GABA-A receptor

Assets acting on this target.

Class
GABA-A receptor positive allosteric modulator

The GABA-A receptor is a chloride-channel embedded in nerve cell membranes that responds to gamma-aminobutyric acid (GABA), the principal inhibitory chemical messenger in the brain. When GABA binds, the channel opens, chloride ions flow into the neuron, and the cell becomes less likely to fire. Positive allosteric modulators (PAMs) do not open this channel by themselves in the classic case; instead, they bind at sites separate from where GABA binds and increase how effectively GABA opens the channel, amplifying inhibitory signaling. Because GABA-A receptors are built from different combinations of subunit proteins, several distinct allosteric sites exist, and different chemical classes of PAMs (benzodiazepines, barbiturates, and neurosteroids) each target a different one, producing overlapping but not identical effects on the nervous system. This mechanism is central to controlling seizures, since strengthening inhibition can halt the excessive, synchronized neuronal firing that defines epilepsy and status epilepticus. It also underlies treatments for acute anxiety, procedural sedation, and, in the case of neurosteroid-based modulators, conditions tied to hormonal fluctuation. The shared endpoint across these agents is dampening neuronal excitability broadly, making the receptor a foundational target across neurology and psychiatry.

By indication

Related mechanisms

GABA-A receptor drugs compared

15 drugs, stage by indication
15 drugs acting on GABA-A receptor: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
Clobazam (Onfi)OnfiH. Lundbeck, Lundbeck LLCsmall moleculeApprovedApproved in Developmental and Epileptic Encephalopathies; Approved in Epilepsy; Approved in Lennox-Gastaut Syndrome
Diazepam (Diastat)DiastatBausch Healthsmall moleculeApprovedApproved in Epilepsy
Diazepam (Valium)ValiumChong Kun Dang Pharmaceutical, Pharmanovia, Waylis Therapeutics LLCsmall moleculeApprovedApproved in Epilepsy
Diazepam (Valtoco)ValtocoNeurelis, Inc.small moleculeApprovedApproved in Epilepsy
GanaxoloneImmedica Pharma ABsmall moleculeApprovedApproved in Developmental and Epileptic Encephalopathies; Approved in Epilepsy
LorazepamHikma Pharmaceuticals PLCsmall moleculeApprovedApproved in Epilepsy
Midazolam (Nayzilam)NayzilamUCBsmall moleculeApprovedApproved in Epilepsy
Phenobarbital sodium injection (Sezaby)Sun Pharmaceutical Industriessmall moleculeApprovedApproved in Epilepsy
StiripentolBiocodexsmall moleculeApprovedApproved in Developmental and Epileptic Encephalopathies; Approved in Dravet Syndrome; Approved in Epilepsy; Phase 3 in Primary Hyperoxaluria Type 1
Diazepam (Libervant)LibervantAquestive Therapeutics, Inc., Eton Pharmaceuticals, Inc., Pharmanoviasmall moleculePhase 3Phase 3 in Epilepsy
KH607Chengdu Kanghong Pharmaceuticalsmall moleculePhase 3Phase 3 in Major Depressive Disorder
Staccato AlprazolamNova Pneuma Inc., UCBsmall moleculePhase 3Phase 3 in Epilepsy
GlyphAllo (allopregnanolone prodrug)SPT-300PureTech Health, Seaport Therapeuticssmall moleculePhase 2Phase 2 in Major Depressive Disorder
HS-10353Hansoh Pharmaceutical Groupsmall moleculePhase 2Phase 2 in Major Depressive Disorder
RemimazolamJiangsu Hengrui Pharmaceuticalssmall moleculePhase 1Not recorded

← all mechanisms